Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ZW25 shows potential in multiple cancer types
December 2019
SHARING OPTIONS:

BARCELONA, Spain—This year's European Society of Medical Oncology meeting saw Zymeworks present interim Phase 1 data on its ZW25 compound, with encouraging results in biliary (bile duct), colorectal, gynecological and gastroesophageal cancers. The compound is a HER2-targeted bispecific antibody that binds to two distinct sites on HER2, resulting in dual HER2 signal blockage, increased binding and removal of HER2 protein from the surface of cells, and potent effector function. Of 58 patients (46 evaluable) with HER2-expressing solid tumors other than breast cancer, Zymeworks reported a disease control rate of 72 percent across all cohorts, including 16 partial responses and 17 individuals with stable disease. As a single agent, ZW25 demonstrated anti-cancer activity and was well tolerated by heavily pretreated patients.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.